DAE HWA Pharmaceutical Co., Ltd. (KOSDAQ:067080)
13,940
-210 (-1.48%)
At close: Apr 9, 2026
DAE HWA Pharmaceutical Revenue
In the year 2025, DAE HWA Pharmaceutical had annual revenue of 143.06B KRW, down -4.25%. DAE HWA Pharmaceutical had revenue of 33.70B in the quarter ending December 31, 2025, a decrease of -15.97%.
Revenue
143.06B
Revenue Growth
-4.25%
P/S Ratio
1.71
Revenue / Employee
464.48M
Employees
308
Market Cap
245.23B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 143.06B | -6.35B | -4.25% |
| Dec 31, 2024 | 149.41B | 8.05B | 5.69% |
| Dec 31, 2023 | 141.36B | 9.45B | 7.16% |
| Dec 31, 2022 | 131.91B | 14.75B | 12.59% |
| Dec 31, 2021 | 117.16B | 7.81B | 7.15% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| NOVAREX | 404.26B |
| DongKoo Bio & Pharma | 242.69B |
| Kyung Dong Pharmaceutical | 196.27B |
| GREEN CROSS WellBeing | 164.68B |
| OPTUS Pharmaceutical | 87.16B |
| High Tech Pharm | 70.18B |
| Vivozon Pharmaceutical | 59.34B |
| HEM Pharma | 12.98B |